SenseTime and Sinopharm Capital have contributed to the oncology surgical device developer’s latest round, which will fund sales, marketing, product and technology improvement.
China-based cancer therapy equipment manufacturer Hygea Medical Technology secured RMB500m ($77m) in series C funding today from investors including image recognition technology producer SenseTime and pharmaceutical firm Sinopharm. Venture capital firm China Growth Capital led the round, which included BioTrack Capital, Chengwei Chuangban, Grand Flight, Junyida Capital, Potential Capital, Sharewin Investment, Suiyong Capital, Yuanhui Capital…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.